G1 Therapeutics (NASDAQ: GTHX)
Some price data may be temporarily unavailable.
G1 Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
G1 Therapeutics Company Info
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
News & Analysis
2 Top Cancer Treatment Stocks to Buy in June
If you have cash to spare, these cancer stocks are set to soar.
Are These 3 Beaten-Down Biotech Stocks Bargains Now?
Some investors think the market's been too hard on these drugmakers.
Why G1 Therapeutics Stock Plunged 37.2% in September
After soaring almost 70% year to date, G1 shares were under pressure following new data on two drug candidates.
Winners and Losers of Europe’s Big Cancer Meeting
Unfortunately there were more of the latter.
Why Cal-Maine Foods, G1 Therapeutics, and Teekay LNG Partners Slumped Today
Tough going kept these stocks from joining the rally.
These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?
These stocks were huge winners last week. But can their momentum continue?
Why SunPower, Snap, and G1 Therapeutics Jumped Today
Favorable comments from analysts helped some of these power players stand out on a strong day for the market.
Why G1 Therapeutics Is Soaring 16% Today
The clinical-stage biopharmaceutical company is on track to file for FDA approval of its first drug, trilaciclib.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.